WELCOME TO THE JUNGLE!

[was CA$H]

Standard & Poor's Initiates Factual Stock Report Coverage on GeoVax Labs, Inc.

Feb 5, 2009 8:00:00 AM

NEW YORK--(BUSINESS WIRE)-- Standard & Poor's announced today that it has commenced Factual Stock Report coverage on GeoVax Labs, Inc.

GeoVax Labs, Inc. (BB:GOVX), is a biotechnology company developing human vaccines for diseases caused by HIV-1 and other infectious agents. GeoVax seeks to develop, manufacture, license and commercialize human vaccines for diseases caused by Human Immunodeficiency Virus (HIV) and other infectious agents. It has exclusively licensed from Emory University certain Acquired Immune Deficiency Syndrome (AIDS) vaccine technology which was developed in collaboration with the National Institutes of Health and the Centers for Disease Control and Prevention.

The Company's HIV/AIDS vaccine candidates have successfully completed preclinical efficacy testing in non-human primates and Phase 1 clinical testing trials in humans. The human trial was conducted by the HIV Vaccine Trials Network (HVTN), and funded by the National Institute of Allergy and Infectious Disease (NIAID), a division of the National Institutes of Health (NIH), and was satisfactorily concluded in June 2004. HVTN has concluded a series of four additional Phase 1 human trials, evaluating the company's AIDS vaccines at several locations in the United States. One trial began in April 2006, a second trial began in September 2006, and the third and fourth trials began in July 2007.

In December 2008, GeoVax announced that the launch of its Phase 2a human vaccine trials will take place in 12 sites across North and South America. These trials are also being conducted by HVTN and funded by NIAID. The resource support provided by NIAID is supplemented by a 5 year, $15 million federal grant awarded to GeoVax in October 2007 by the NIH to further advance GeoVax's vaccine development efforts.

This report will also be accessible on an ongoing basis to the investment community ---- scores of buy-side institutions and sell-side firms that utilize S&P research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts.

About Standard & Poor's Factual Stock Reports

This Standard & Poor's service provides factual research coverage enabling information about GeoVax Labs, Inc. and other securities to reach a wide investor audience of Buy and Sell-side investors, helping them understand a company's fundamentals and business prospects. Currently profiling over 1,000 issuers, S&P Factual Stock Reports increase market awareness for issuers in the investment community with insightful commentary and key statistics/information. Updated weekly with the latest pricing, trading volume, and other data, the reports include recent developments, a financial review, key operating information, Industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, performance charts, business summary, fundamental data, and news. Because coverage of these reports is sponsored by the issuer, S&P does not offer investment opinions concerning the advisability of investing in these stocks.

Standard & Poor's Factual Stock Reports are produced separately from any other analytic activity of Standard & Poor's. Standard & Poor's Factual Report research has no access to non-public information received by other units of Standard & Poor's. Standard & Poor's does not trade on its own account.

Note: All U.S. and Canadian Companies listed on a National Exchange (not covered by S&P's STARS research) are eligible to obtain this coverage.

About Standard & Poor's

Standard & Poor's, a division of The McGraw-Hill Companies (NYSE: MHP), is the world's foremost provider of financial market intelligence, including independent credit ratings, indices, risk evaluation, investment research and data. With approximately 8,500 employees, including wholly owned affiliates, located in 23 countries, Standard & Poor's is an essential part of the world's financial infrastructure and has played a leading role for more than 140 years in providing investors with the independent benchmarks they need to feel more confident about their investment and financial decisions. For more information, visit http://www.standardandpoors.com.





Source: Standard & Poor's